NCT02508207View on ClinicalTrials.gov

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

Tezacaftor/Ivacaftor

Tezacaftor/Ivacaftor FDC

DRUG

Ivacaftor

DRUG

Tezacaftor/Ivacaftor matching placebo

DRUG

Ivacaftor matching placebo

Trial Locations (7)

Unknown

Birmingham

Indianapolis

Baltimore

Chapel Hill

Cincinnati

Toledo

Pittsburgh

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02508207 - A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | Biotech Hunter | Biotech Hunter